Infliximab Plus MTX for JIA | Arthritis Information
PHILADELPHIA, Pennsylvania—Infliximab plus methotrexate (MTX) bests combinations of traditional disease modifying drugs and/or MTX alone for the treatment of polyarticular juvenile idiopathic arthritis, according to randomized clinical trial of 60 patients presented at the American College of Rheumatology Annual Scientific Meeting in Philadelphia, PA.1
This study in children is in line with findings in adult rheumatology,” said lead researcher Pirjo Tynjälä, MD, PhD, of the Hosptial of Children and Adolescents, at Helsinki University Central Hospital in Helsinki, Finland, in a press release. “The current target of the treatment in JIA is minimal disease activity and, preferably, remission. When that is the target, in polyarticular JIA, combination therapy with new biologic agents plus methotrexate is more effective than combination therapy with ‘older’ synthetic anti-rheumatic drugs, and clearly more effective than methotrexate alone.”
http://www.mskreport.com/articles.cfm?articleID=3447
Copyright ArthritisInsight.com